In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp

Diagnostic Microbiology and Infectious Disease

Volumn 45, Issue 2, 2003, Pages 131-135

  Del Carmen Serrano, María ^a   Valverde Conde, Anastasio ^a   Chávez, Mónica ^a   Bernal, Samuel ^a   Claro, Rosa María ^a   Pemán, Javier ^b   Ramirez, Mercedes ^a   Martín Mazuelos, Estrella ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; DILUTION; DRUG EFFICACY; EVALUATION; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC; PYRIMIDINES; TIME FACTORS; TRIAZOLES;

EID: 0037332131     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00507-2     Document Type: Article

References (34)

1. Abraham O.C., Manavathu E.K., Cutright J.L., Chandrasekar P.H. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis. 33:1999;7-11.
2. Arikan S., Lozano-Chiu M., Paetznick V., Nangia S., Rex J.H. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against isolates of Aspergillus and Fusarium species. J Clin Microbiol. 37:1999;3946-3951.
3. Arikan S., Lozano-Chiu M., Paetznick V., Rex J.H. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother. 45:2001;327-330.
4. Barry A.L., Brown S.D. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother. 40:1996;1948-1949.
5. Chandrasekar P.H., Cutright J., Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother. 45:2000;673-676.
6. Chávez M., Bernal S., Valverde A., Gutierrez M.J., Quindos G., Martín Mazuelos E. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents oral Candida spp. Isolates from HIV-infected patients. J Antimicrob Chemother. 44:1999;697-700.
7. Cuenca-Estrella M., Rodriguez-Tudela J.L., Mellado E., Martinez-Suarez J.V., Monzon A. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother. 42:1998;531-533.
8. Cuenca-Estrella M., Mellado E., Diaz-Guerra T.M., Monzon A., Rodríguez-Tudela J.L. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother. 46:2000;475-477.
9. Del Poeta M., Schell W.A., Perfect J.R. In vitro antifungal activity of pneimocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother. 41:1997;1835-1836.
10. Denning D.W. Therapeutic outcome invasive aspergillosis. Clin Infect Dis. 23:1996;608-615.
11. Denning D.W., del Favero A., Gluckman E., Rhunke M., Yonren S., Troke P., Sarantis N. The efficacy and tolerability of UK 109,496 (voriconazole) in the treatment of invasive aspergillosis. Clin Infect Dis. 34:2002;563-571.
12. Denning D.W. Invasive aspergillosis. Clin Infect Dis. 26:1998;781-805.
13. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991(743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 36:1998;2950-2956.
14. Johnson E.M., Szekely A., Warnock D.W. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 42:1998;741-745.
15. Kirkpatrick W.R., McAtee R.K., Fothergill A.W., Rinaldi M.G., Patterson T.F. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother. 44:2000;2865-2868.
16. Krishnarao T.V., Galgiani J.N. Comparison of the in vitro activities of echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 41:1997;1957-1960.
17. Manavathu E.K., Cutright J.L., Loebenberg D., Chandrasekar P.H. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. To amphotericin B, itraconazole, voriconazole and posaconazole(SCH 56592). J Antimicrob Chemother. 42:2000;229-234.
18. Manavathu E.K., Abraham O.C., Chandrasekar P.H. Isolation and in vitro susceptibility to amphotericine B, itraconazole and posaconazole of voriconazole-resistant laboartory isolates of Aspergillus fumigatus. Clin Microbiol Infect. 7:2001;130-137.
19. Marco F., Pfaller M.A., Messer S., Jones R.N. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 42:1998;161-163.
20. Murphy M., Bernard E.M., Ishimaru T., Armstrong D. Activity of Voriconazole (UK-109,496) against clinical isolates of Aspergillus species an its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 41:1997;696-698.
21. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast-Approved Standard. M27A. 1997;NCCLS, Villanova, PA.
22. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi; Proposed Standard. NCCLS document M38-P. 1998.
23. Oakley K.L., Moore C.B., Denning D.W. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother. 42:1998;2726-2730.
24. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., Rinaldi M.G., Stevens D.A., Graybill J.R. Invasive aspergillosis Disease spectrum, treatment practices, and outcomes. Medicine. 79:2000;250-260.
25. Pfaller M.A., Messer S.A., Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob Agents Chemother. 41:1997;763-766.
26. Pfaller M.A., Marco F., Mecer S.A., Jones R.N. In vitro activity of two equinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 30:1998;251-255.
27. Pfaller M.A., Jones R.N., Doern G.V., et al. International surveillance of bloodstream infections due to Candida species in the European SENTRY Program Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis. 35:1999;19-25.
28. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi Report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother. 46:2002;1032-1037.
29. Radford S.A., Johnson E.M., Warnock D.W. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 41:1997;841-843.
30. Stevens D.A., Kan V.L., Judson M.A., Morrison V.A., Dummer S., Denning D.W., Bennett J.E., Walsh T.J., Patterson T.F., Pankey G.A. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis. 30:2000;696-709.
31. Uzun O., Kocagoz S., Cetinkaya Y., Arikan S., Unal S. In vitro activity of a new echinocandin, LY303366, compared with tose of amphotericin B an fluconazole against clinical yeast isolates. Antimicrob Agents Chemother. 41:1997;1156-1157.
32. Uzun O., Arikan S., Kocagoz S., Sancak B., Unal S. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis. 38:2000;101-107.
33. Verweij P.E., Mensink M., Rijs A.J., Donnelly J.P., Meis J.F., Denning D.W. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother. 42:1998;389-392.
34. Zhanel G.G., Karlowsky J.A., Harding G.A.J., Balko T.V., Zelenitsky S.A., Friesen M., Kabani A., Turik M., Hoban D.J. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 41:1997;863-865.